1. Amgen buying drug discovery biotech Nuevolution for $167M — Novartis’ asthma drug beats GSK’s Advair in trial — Lilly’s mirikizumab succeeds in phase 2 Crohn’s trial -- See more on our front page news

    Got questions about whistleblowing?: Ask a Whistleblower Attorney
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 17, 2019 at 7:32 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    via AstraZeneca’s experimental cancer drug cediranib was originally developed to inhibit VEGF, a protein that prompts the growth of the blood vessels tumors need to survive. But in clinical trials it hasn’t proven to be all that effective, failing to stack up to Roche’s anti-VEGF blockbuster Avastin.

    article source